Albireo Pharma, Inc. (NASDAQ:ALBO) Expected to Post Q2 2022 Earnings of ($0.76) Per Share

Albireo Pharma, Inc. (NASDAQ:ALBOGet Rating) – Equities researchers at Wedbush issued their Q2 2022 earnings estimates for Albireo Pharma in a research report issued on Tuesday, May 17th. Wedbush analyst A. Argyrides expects that the biopharmaceutical company will post earnings per share of ($0.76) for the quarter. Wedbush currently has a “Buy” rating and a $72.00 price objective on the stock. Wedbush also issued estimates for Albireo Pharma’s Q3 2022 earnings at ($0.51) EPS, Q4 2022 earnings at ($0.33) EPS, FY2022 earnings at ($3.78) EPS, Q1 2023 earnings at ($0.89) EPS, Q2 2023 earnings at ($0.87) EPS, Q3 2023 earnings at ($0.64) EPS, Q4 2023 earnings at ($0.51) EPS, FY2023 earnings at ($2.91) EPS, FY2024 earnings at ($1.51) EPS, FY2025 earnings at $5.85 EPS and FY2026 earnings at $11.99 EPS.

ALBO has been the subject of a number of other research reports. StockNews.com started coverage on shares of Albireo Pharma in a research note on Thursday, March 31st. They issued a “hold” rating for the company. Robert W. Baird cut their price objective on Albireo Pharma from $72.00 to $66.00 in a research report on Tuesday. Two equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Buy” and an average target price of $62.00.

NASDAQ:ALBO opened at $21.16 on Thursday. The company has a debt-to-equity ratio of 0.06, a quick ratio of 5.93 and a current ratio of 5.93. Albireo Pharma has a 12 month low of $20.30 and a 12 month high of $37.86. The company’s 50-day moving average price is $31.79 and its two-hundred day moving average price is $28.66.

Albireo Pharma (NASDAQ:ALBOGet Rating) last issued its earnings results on Monday, May 16th. The biopharmaceutical company reported ($2.19) EPS for the quarter, missing the consensus estimate of ($2.02) by ($0.17). Albireo Pharma had a negative net margin of 72.02% and a negative return on equity of 72.90%. During the same quarter last year, the company posted ($2.29) earnings per share.

Large investors have recently made changes to their positions in the business. Russell Investments Group Ltd. bought a new position in shares of Albireo Pharma in the 1st quarter valued at about $36,000. Advisor Group Holdings Inc. boosted its stake in Albireo Pharma by 2,151.5% in the third quarter. Advisor Group Holdings Inc. now owns 2,184 shares of the biopharmaceutical company’s stock valued at $68,000 after acquiring an additional 2,087 shares during the last quarter. Lazard Asset Management LLC bought a new position in Albireo Pharma in the first quarter valued at approximately $75,000. Zurcher Kantonalbank Zurich Cantonalbank acquired a new stake in Albireo Pharma during the 4th quarter worth $114,000. Finally, Ensign Peak Advisors Inc bought a new stake in shares of Albireo Pharma during the 4th quarter valued at $126,000. 82.99% of the stock is owned by hedge funds and other institutional investors.

In related news, CEO Ronald Harold Wilfred Cooper sold 907 shares of the firm’s stock in a transaction that occurred on Friday, April 22nd. The shares were sold at an average price of $33.11, for a total value of $30,030.77. Following the completion of the sale, the chief executive officer now owns 56,082 shares of the company’s stock, valued at $1,856,875.02. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Insiders have sold 1,872 shares of company stock worth $61,139 over the last three months. 5.00% of the stock is owned by insiders.

About Albireo Pharma (Get Rating)

Albireo Pharma, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of novel bile acid modulators to treat orphan pediatric liver diseases and other liver or gastrointestinal diseases and disorders. The company offers Bylvay for the treatment of progressive familial intrahepatic cholestasis, as well as in Phase III clinical trial for treating biliary atresia, alagille syndrome, and rare and life-threatening disorder to children; and Elobixibat for the treatment of chronic constipation and other functional diseases.

Featured Articles

Earnings History and Estimates for Albireo Pharma (NASDAQ:ALBO)

Receive News & Ratings for Albireo Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Albireo Pharma and related companies with MarketBeat.com's FREE daily email newsletter.